RVTY
Revvity, Inc.
Price Chart
Latest Quote
$100.00
+2.18 (+2.23%)
Current Price
| Previous Close | $97.82 |
| Open | $97.98 |
| Day High | $100.72 |
| Day Low | $97.92 |
| Volume | 2,170,304 |
Stock Information
| Quarterly Dividend / Yield | $0.28 / 0.28% |
| Shares Outstanding | 111.56M |
| Quarterly Dividend Yield | 0.28% |
| Quarterly Dividend | $0.28 |
| Total Debt | $3.35B |
| Cash Equivalents | $860.32M |
| Revenue | $2.90B |
| Net Income | $239.11M |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Market Cap | $11.16B |
| P/E Ratio | 48.08 |
| EPS (TTM) | $2.08 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $13.65B |
| Sales | $2.90B |
| Income | $239.11M |
| Book/sh | $64.34 |
| Cash/sh | $7.71 |
| Employees | 11K |
Financial Ratios
| Quick Ratio | 1.25 |
| Current Ratio | 1.72 |
| Debt/Eq | 46.64 |
| EPS Growth TTM | -3.60% |
Returns & Margins
| ROA | 2.27% |
| ROE | 3.23% |
| Gross Margin | 54.32% |
| Operating Margin | 12.35% |
| Profit Margin | 8.26% |
Ownership
| Insider Ownership | 0.36% |
| Institutional Ownership | 105.82% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 17.15 |
| PEG | 0.61 |
| P/S | 3.84 |
| P/B | 1.55 |
Analyst Data
| Recommendation | buy |
| Target Price | $113.64 |
Technical Indicators
| SMA20 | $100.05 |
| SMA50 | $95.48 |
| SMA200 | $95.43 |
| RSI | 41.88 |
| ATR | 3.8807 |
| Shares Float | 102.14M |
| Short Float | 11.75% |
| Short Ratio | 5.28 |
| Volatility | 1.11 |
| Rel Volume | 1.44 |
Performance History
| Week | -1.50% |
| Month | +4.31% |
| Quarter | +16.70% |
| 6 Months | +4.02% |
| YTD | +2.03% |
| Year | +6.51% |
| 3 Years | -12.27% |
| 5 Years | -31.08% |
| 10 Years | +93.76% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $100.00 | 2,170,300 |
| 2026-06-17 | $97.82 | 858,900 |
| 2026-06-16 | $101.22 | 1,303,100 |
| 2026-06-15 | $100.55 | 942,400 |
| 2026-06-12 | $99.66 | 927,400 |
| 2026-06-11 | $101.52 | 1,800,700 |
| 2026-06-10 | $101.29 | 1,100,000 |
| 2026-06-09 | $104.13 | 1,243,100 |
| 2026-06-08 | $100.30 | 1,280,400 |
| 2026-06-05 | $98.37 | 868,600 |
| 2026-06-04 | $102.40 | 865,000 |
| 2026-06-03 | $101.07 | 1,152,600 |
| 2026-06-02 | $100.39 | 1,421,600 |
| 2026-06-01 | $100.52 | 2,165,800 |
| 2026-05-29 | $104.55 | 2,338,300 |
| 2026-05-28 | $101.22 | 4,082,300 |
| 2026-05-27 | $96.79 | 925,600 |
| 2026-05-26 | $96.83 | 2,453,900 |
| 2026-05-22 | $96.95 | 942,800 |
| 2026-05-21 | $95.38 | 1,287,000 |
| 2026-05-20 | $94.80 | 1,423,400 |
| 2026-05-19 | $95.87 | 1,049,100 |
About Revvity, Inc.
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
đ° Latest News
Is Revvity Stock Underperforming the Nasdaq?
Barchart âĸ 2026-06-19T14:47:51Z
2 Profitable Stocks with Impressive Fundamentals and 1 We Turn Down
StockStory âĸ 2026-06-15T12:36:07Z
Revvity (RVTY) Valuation Check After China Immunodiagnostics Exit Plan And Solid First Quarter Results
Simply Wall St. âĸ 2026-06-08T21:17:46Z
Why Is Revvity (RVTY) Up 2% Since Last Earnings Report?
Zacks âĸ 2026-06-04T15:30:27Z
Research Tools & Consumables Stocks Q1 In Review: Revvity (NYSE:RVTY) Vs Peers
StockStory âĸ 2026-06-01T16:08:51Z
Is Danaher Stock Underperforming the S&P 500?
Barchart âĸ 2026-05-29T14:28:21Z
Revvity Stock: Analyst Estimates & Ratings
Barchart âĸ 2026-05-22T14:00:15Z
Revvity's (NYSE:RVTY) Conservative Accounting Might Explain Soft Earnings
Simply Wall St. âĸ 2026-05-20T10:21:29Z
The Top 5 Analyst Questions From Revvityâs Q1 Earnings Call
StockStory âĸ 2026-05-15T11:16:55Z
RVTY Expands Endocrine Diagnostics With FDA-Cleared Testosterone Assay
Zacks âĸ 2026-05-14T15:59:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $1,291,686,000 | $1,217,367,000 | $1,210,880,000 | $1,321,992,000 |
| Cost Of Revenue | $1,291,686,000 | $1,217,367,000 | $1,210,880,000 | $1,321,992,000 |
| Total Revenue | $2,856,051,000 | $2,755,026,000 | $2,750,571,000 | $3,311,822,000 |
| Operating Revenue | $2,856,051,000 | $2,755,026,000 | $2,750,571,000 | $3,311,822,000 |
| Expenses | ||||
| Interest Expense | $92,185,000 | $96,278,000 | $98,813,000 | $103,955,000 |
| Total Expenses | $2,499,416,000 | $2,408,285,000 | $2,450,009,000 | $2,569,123,000 |
| Other Income Expense | $-27,276,000 | $-7,527,000 | $-90,904,000 | $9,504,000 |
| Other Non Operating Income Expenses | $-871,000 | $-8,508,000 | $-19,006,000 | $33,158,000 |
| Net Non Operating Interest Income Expense | $-61,082,000 | $-23,088,000 | $-26,682,000 | $-100,366,000 |
| Interest Expense Non Operating | $92,185,000 | $96,278,000 | $98,813,000 | $103,955,000 |
| Operating Expense | $1,207,730,000 | $1,190,918,000 | $1,239,129,000 | $1,247,131,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $239,883,000 | $283,071,000 | $179,503,000 | $512,676,000 |
| Net Interest Income | $-61,082,000 | $-23,088,000 | $-26,682,000 | $-100,366,000 |
| Interest Income | $31,103,000 | $73,190,000 | $72,131,000 | $3,589,000 |
| Normalized Income | $263,489,070 | $282,193,005 | $250,034,938 | $531,280,096 |
| Net Income From Continuing And Discontinued Operation | $241,201,000 | $270,385,000 | $693,094,000 | $569,179,000 |
| Total Operating Income As Reported | $356,635,000 | $346,741,000 | $300,562,000 | $742,699,000 |
| Net Income Common Stockholders | $241,201,000 | $270,385,000 | $693,094,000 | $569,179,000 |
| Net Income | $241,201,000 | $270,385,000 | $693,094,000 | $569,179,000 |
| Net Income Including Noncontrolling Interests | $241,201,000 | $270,385,000 | $693,094,000 | $569,179,000 |
| Net Income Discontinuous Operations | $1,318,000 | $-12,686,000 | $513,591,000 | $56,503,000 |
| Net Income Continuous Operations | $239,883,000 | $283,071,000 | $179,503,000 | $512,676,000 |
| Pretax Income | $268,277,000 | $316,126,000 | $182,976,000 | $651,837,000 |
| Interest Income Non Operating | $31,103,000 | $73,190,000 | $72,131,000 | $3,589,000 |
| Operating Income | $356,635,000 | $346,741,000 | $300,562,000 | $742,699,000 |
| Gross Profit | $1,564,365,000 | $1,537,659,000 | $1,539,691,000 | $1,989,830,000 |
| Special Income Charges | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $2.07 | $2.20 | $5.55 | $4.58 |
| Basic EPS | $2.15 | $2.24 | $5.62 | $4.59 |
| Other | ||||
| Tax Effect Of Unusual Items | $-2,798,930 | $103,005 | $-1,366,062 | $-5,049,904 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $792,207,000 | $839,272,000 | $785,456,000 | $1,206,446,000 |
| Total Unusual Items | $-26,405,000 | $981,000 | $-71,898,000 | $-23,654,000 |
| Total Unusual Items Excluding Goodwill | $-26,405,000 | $981,000 | $-71,898,000 | $-23,654,000 |
| Reconciled Depreciation | $405,340,000 | $427,849,000 | $431,769,000 | $427,000,000 |
| EBITDA (Bullshit earnings) | $765,802,000 | $840,253,000 | $713,558,000 | $1,182,792,000 |
| EBIT | $360,462,000 | $412,404,000 | $281,789,000 | $755,792,000 |
| Diluted Average Shares | $116,595,000 | $122,822,000 | $124,812,000 | $126,426,000 |
| Basic Average Shares | $112,281,000 | $120,646,000 | $123,426,000 | $126,300,000 |
| Diluted NI Availto Com Stockholders | $241,201,000 | $270,385,000 | $693,094,000 | $569,179,000 |
| Tax Provision | $28,394,000 | $33,055,000 | $3,473,000 | $139,161,000 |
| Gain On Sale Of Security | $-26,405,000 | $981,000 | $-71,898,000 | $-23,654,000 |
| Research And Development | $215,840,000 | $196,844,000 | $216,578,000 | $221,617,000 |
| Selling General And Administration | $991,890,000 | $994,074,000 | $1,022,551,000 | $1,025,514,000 |
| Restructuring And Mergern Acquisition | - | - | - | - |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-1,710,136,000 | $-1,437,666,000 | $-1,683,132,000 | $-2,476,066,000 |
| Total Assets | $12,168,411,000 | $12,392,478,000 | $13,564,665,000 | $14,129,855,000 |
| Total Non Current Assets | $9,928,664,000 | $10,042,870,000 | $10,563,574,000 | $10,841,297,000 |
| Other Non Current Assets | $323,480,000 | $288,397,000 | $342,966,000 | $311,054,000 |
| Goodwill And Other Intangible Assets | $8,960,496,000 | $9,104,540,000 | $9,555,871,000 | $9,858,942,000 |
| Other Intangible Assets | $2,347,003,000 | $2,640,921,000 | $3,022,321,000 | $3,377,174,000 |
| Current Assets | $2,239,747,000 | $2,349,608,000 | $3,001,091,000 | $3,288,558,000 |
| Other Current Assets | $195,719,000 | $186,225,000 | $337,139,000 | $122,254,000 |
| Inventory | $379,497,000 | $367,587,000 | $428,062,000 | $405,462,000 |
| Receivables | $744,671,000 | $632,400,000 | $632,811,000 | $612,780,000 |
| Accounts Receivable | $744,671,000 | $632,400,000 | $632,811,000 | $612,780,000 |
| Cash Cash Equivalents And Short Term Investments | $919,860,000 | $1,163,396,000 | $1,603,079,000 | $454,358,000 |
| Cash And Cash Equivalents | $919,860,000 | $1,163,396,000 | $913,163,000 | $454,358,000 |
| Assets Held For Sale Current | - | - | $0 | $1,693,704,000 |
| Debt | ||||
| Net Debt | $2,300,204,000 | $1,987,322,000 | $2,986,479,000 | $3,939,918,000 |
| Total Debt | $3,398,207,000 | $3,325,805,000 | $4,065,295,000 | $4,595,461,000 |
| Long Term Debt And Capital Lease Obligation | $2,779,344,000 | $3,301,981,000 | $3,310,517,000 | $4,093,315,000 |
| Long Term Debt | $2,631,236,000 | $3,150,476,000 | $3,177,770,000 | $3,923,347,000 |
| Current Debt And Capital Lease Obligation | $618,863,000 | $23,824,000 | $754,778,000 | $502,146,000 |
| Current Debt | $588,828,000 | $242,000 | $721,872,000 | $470,929,000 |
| Other Current Borrowings | $588,828,000 | $242,000 | $721,872,000 | $470,929,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $4,918,051,000 | $4,725,604,000 | $5,691,926,000 | $6,746,979,000 |
| Total Non Current Liabilities Net Minority Interest | $3,586,805,000 | $4,072,504,000 | $4,241,463,000 | $5,202,496,000 |
| Other Non Current Liabilities | $807,461,000 | $770,523,000 | $930,946,000 | $1,109,181,000 |
| Current Liabilities | $1,331,246,000 | $653,100,000 | $1,450,463,000 | $1,544,483,000 |
| Current Deferred Liabilities | $160,194,000 | $140,212,000 | $135,555,000 | $135,531,000 |
| Payables And Accrued Expenses | $504,061,000 | $444,881,000 | $516,851,000 | $581,958,000 |
| Payables | $266,029,000 | $241,866,000 | $292,280,000 | $318,451,000 |
| Total Tax Payable | $80,565,000 | $74,403,000 | $88,159,000 | $45,625,000 |
| Income Tax Payable | $80,565,000 | $74,403,000 | $88,159,000 | $45,625,000 |
| Accounts Payable | $185,464,000 | $167,463,000 | $204,121,000 | $272,826,000 |
| Liabilities Heldfor Sale Non Current | - | - | - | $0 |
| Non Current Deferred Liabilities | - | - | - | $1,109,181,000 |
| Non Current Deferred Taxes Liabilities | - | - | - | $1,109,181,000 |
| Other Current Liabilities | - | - | - | $272,865,000 |
| Equity | ||||
| Common Stock Equity | $7,250,360,000 | $7,666,874,000 | $7,872,739,000 | $7,382,876,000 |
| Total Equity Gross Minority Interest | $7,250,360,000 | $7,666,874,000 | $7,872,739,000 | $7,382,876,000 |
| Stockholders Equity | $7,250,360,000 | $7,666,874,000 | $7,872,739,000 | $7,382,876,000 |
| Gains Losses Not Affecting Retained Earnings | $-222,135,000 | $-396,105,000 | $-276,692,000 | $-447,497,000 |
| Other Equity Adjustments | $-222,135,000 | $-396,105,000 | $-276,692,000 | $-447,497,000 |
| Retained Earnings | $6,054,314,000 | $5,845,223,000 | $5,609,212,000 | $4,951,018,000 |
| Other | ||||
| Ordinary Shares Number | $112,281,000 | $120,646,000 | $123,426,000 | $126,300,000 |
| Share Issued | $112,281,000 | $120,646,000 | $123,426,000 | $126,300,000 |
| Tangible Book Value | $-1,710,136,000 | $-1,437,666,000 | $-1,683,132,000 | $-2,476,066,000 |
| Invested Capital | $10,470,424,000 | $10,817,592,000 | $11,772,381,000 | $11,777,152,000 |
| Working Capital | $908,501,000 | $1,696,508,000 | $1,550,628,000 | $1,744,075,000 |
| Capital Lease Obligations | $178,143,000 | $175,087,000 | $165,653,000 | $201,185,000 |
| Total Capitalization | $9,881,596,000 | $10,817,350,000 | $11,050,509,000 | $11,306,223,000 |
| Additional Paid In Capital | $1,305,900,000 | $2,097,110,000 | $2,416,793,000 | $2,753,055,000 |
| Capital Stock | $112,281,000 | $120,646,000 | $123,426,000 | $126,300,000 |
| Common Stock | $112,281,000 | $120,646,000 | $123,426,000 | $126,300,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $148,108,000 | $151,505,000 | $132,747,000 | $169,968,000 |
| Current Deferred Revenue | $160,194,000 | $140,212,000 | $135,555,000 | $135,531,000 |
| Current Capital Lease Obligation | $30,035,000 | $23,582,000 | $32,906,000 | $31,217,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $48,128,000 | $44,183,000 | $43,279,000 | $51,983,000 |
| Current Accrued Expenses | $238,032,000 | $203,015,000 | $224,571,000 | $263,507,000 |
| Goodwill | $6,613,493,000 | $6,463,619,000 | $6,533,550,000 | $6,481,768,000 |
| Net PPE | $644,688,000 | $649,933,000 | $664,737,000 | $671,301,000 |
| Accumulated Depreciation | $-613,885,000 | $-499,667,000 | $-473,485,000 | $-374,193,000 |
| Gross PPE | $1,258,573,000 | $1,149,600,000 | $1,138,222,000 | $1,045,494,000 |
| Other Properties | $165,439,000 | $167,716,000 | $155,083,000 | $188,351,000 |
| Machinery Furniture Equipment | $669,020,000 | $587,807,000 | $595,124,000 | $482,639,000 |
| Buildings And Improvements | $391,098,000 | $364,556,000 | $358,380,000 | $346,164,000 |
| Land And Improvements | $33,016,000 | $29,521,000 | $29,635,000 | $28,340,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $137,481,000 | $127,894,000 | $161,618,000 | $146,616,000 |
| Work In Process | $68,983,000 | $65,191,000 | $69,176,000 | $68,206,000 |
| Raw Materials | $173,033,000 | $174,502,000 | $197,268,000 | $190,640,000 |
| Other Short Term Investments | - | $0 | $689,916,000 | $0 |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $509,411,000 | $541,651,000 | $9,904,000 | $594,178,000 |
| Operating Activities | ||||
| Operating Cash Flow | $582,933,000 | $628,299,000 | $91,272,000 | $679,810,000 |
| Cash From Discontinued Operating Activities | $-6,023,000 | $-36,656,000 | $-188,115,000 | $7,310,000 |
| Cash Flow From Continuing Operating Activities | $588,956,000 | $664,955,000 | $279,387,000 | $672,500,000 |
| Operating Gains Losses | $3,912,000 | $8,322,000 | $43,493,000 | $-28,871,000 |
| Investing Activities | ||||
| Capital Expenditure | $-73,522,000 | $-86,648,000 | $-81,368,000 | $-85,632,000 |
| Investing Cash Flow | $-17,353,000 | $776,162,000 | $1,313,524,000 | $-132,851,000 |
| Cash From Discontinued Investing Activities | $56,250,000 | $156,897,000 | $2,074,734,000 | $-15,915,000 |
| Cash Flow From Continuing Investing Activities | $-73,603,000 | $619,265,000 | $-761,210,000 | $-116,936,000 |
| Capital Expenditure Reported | $-73,522,000 | $-86,648,000 | $-81,368,000 | $-85,632,000 |
| Net Other Investing Changes | - | - | - | $8,890,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-820,815,000 | $-369,578,000 | $-388,882,000 | $-80,638,000 |
| Financing Cash Flow | $-857,523,000 | $-1,128,235,000 | $-947,121,000 | $-661,803,000 |
| Cash Flow From Continuing Financing Activities | $-857,523,000 | $-1,128,235,000 | $-947,121,000 | $-661,803,000 |
| Net Other Financing Charges | $-6,312,000 | $-8,832,000 | $-10,132,000 | $-767,000 |
| Cash Dividends Paid | $-32,800,000 | $-34,454,000 | $-34,966,000 | $-35,344,000 |
| Common Stock Dividend Paid | $-32,800,000 | $-34,454,000 | $-34,966,000 | $-35,344,000 |
| Net Common Stock Issuance | $-820,815,000 | $-369,578,000 | $-388,882,000 | $-80,638,000 |
| Issuance Of Capital Stock | - | - | - | $14,114,000 |
| Common Stock Issuance | - | - | - | $14,114,000 |
| Other | ||||
| Repayment Of Debt | $-521,000 | $-723,072,000 | $-523,808,000 | $-799,168,000 |
| Interest Paid Supplemental Data | $86,195,000 | $91,092,000 | $94,008,000 | $97,934,000 |
| Income Tax Paid Supplemental Data | $131,350,000 | $154,876,000 | $359,800,000 | $323,077,000 |
| End Cash Position | $921,030,000 | $1,164,452,000 | $914,373,000 | $470,746,000 |
| Beginning Cash Position | $1,164,452,000 | $914,373,000 | $470,746,000 | $619,337,000 |
| Effect Of Exchange Rate Changes | $48,521,000 | $-26,147,000 | $-14,048,000 | $-33,747,000 |
| Changes In Cash | $-291,943,000 | $276,226,000 | $457,675,000 | $-114,844,000 |
| Proceeds From Stock Option Exercised | $2,925,000 | $7,701,000 | $4,344,000 | $14,114,000 |
| Common Stock Payments | $-820,815,000 | $-369,578,000 | $-388,882,000 | $-80,638,000 |
| Net Issuance Payments Of Debt | $-521,000 | $-723,072,000 | $-517,485,000 | $-559,168,000 |
| Net Long Term Debt Issuance | $-521,000 | $-723,072,000 | $-517,485,000 | $-559,168,000 |
| Long Term Debt Payments | $-521,000 | $-723,072,000 | $-523,808,000 | $-799,168,000 |
| Net Investment Purchase And Sale | $-81,000 | $705,913,000 | $-677,756,000 | $-38,291,000 |
| Sale Of Investment | $304,000 | $712,500,000 | $550,153,000 | $8,890,000 |
| Purchase Of Investment | $-385,000 | $-6,587,000 | $-1,227,909,000 | $-47,181,000 |
| Net Business Purchase And Sale | $0 | $0 | $-2,086,000 | $6,987,000 |
| Purchase Of Business | $0 | $0 | $-2,086,000 | $-7,518,000 |
| Change In Working Capital | $-96,781,000 | $-18,305,000 | $-391,346,000 | $-262,968,000 |
| Change In Payables And Accrued Expense | $-10,540,000 | $-47,422,000 | $-368,240,000 | $-280,427,000 |
| Change In Accrued Expense | $-17,885,000 | $-21,397,000 | $-291,814,000 | $-236,623,000 |
| Change In Payable | $7,345,000 | $-26,025,000 | $-76,426,000 | $-43,804,000 |
| Change In Account Payable | $7,345,000 | $-26,025,000 | $-76,426,000 | $-43,804,000 |
| Change In Inventory | $14,782,000 | $45,086,000 | $-14,109,000 | $-48,634,000 |
| Change In Receivables | $-101,023,000 | $-15,969,000 | $-8,997,000 | $66,093,000 |
| Changes In Account Receivables | $-101,023,000 | $-15,969,000 | $-8,997,000 | $66,093,000 |
| Other Non Cash Items | $59,084,000 | $21,658,000 | $38,118,000 | $64,802,000 |
| Stock Based Compensation | $22,847,000 | $37,809,000 | $41,410,000 | $51,518,000 |
| Unrealized Gain Loss On Investment Securities | $11,456,000 | $-7,958,000 | $33,921,000 | $15,754,000 |
| Asset Impairment Charge | $4,784,000 | $22,814,000 | $0 | $0 |
| Deferred Tax | $-61,569,000 | $-110,305,000 | $-97,481,000 | $-107,411,000 |
| Deferred Income Tax | $-61,569,000 | $-110,305,000 | $-97,481,000 | $-107,411,000 |
| Depreciation Amortization Depletion | $405,340,000 | $427,849,000 | $431,769,000 | $427,000,000 |
| Depreciation And Amortization | $405,340,000 | $427,849,000 | $431,769,000 | $427,000,000 |
| Pension And Employee Benefit Expense | $3,639,000 | $9,381,000 | $23,089,000 | $-23,104,000 |
| Net Foreign Currency Exchange Gain Loss | $273,000 | $-1,059,000 | $24,089,000 | $0 |
| Net Income From Continuing Operations | $239,883,000 | $283,071,000 | $179,503,000 | $512,676,000 |
| Issuance Of Debt | - | $0 | $6,323,000 | $240,000,000 |
| Long Term Debt Issuance | - | $0 | $6,323,000 | $240,000,000 |
| Sale Of Business | - | $0 | $153,000 | $14,505,000 |
| Amortization Cash Flow | - | $359,400,000 | $365,100,000 | $370,600,000 |
| Amortization Of Intangibles | - | $359,400,000 | $365,100,000 | $370,600,000 |
| Depreciation | - | $68,500,000 | $66,700,000 | $56,400,000 |
| Gain Loss On Sale Of Business | - | $0 | $0 | $-2,887,000 |
| Net Short Term Debt Issuance | - | - | $6,323,000 | $-1,292,000 |
| Short Term Debt Payments | - | - | - | $-1,292,000 |
| Net Intangibles Purchase And Sale | - | - | - | - |
| Purchase Of Intangibles | - | - | - | - |
Fetched: 2026-06-19